Chemical adjuvants for plasmid DNA vaccines

Vaccine

Volumn 25, Issue 19, 2007, Pages 3731-3741

  Greenland, John R ^a   Letvin, Norman L ^a  

^a HARVARD MEDICAL SCHOOL   (United States)

Author keywords

Adjuvant; Plasmid DNA; Polymer; Vaccine

Indexed keywords

ALGINIC ACID; ALUMINUM POTASSIUM SULFATE; ANTIGEN; BETA CYCLODEXTRIN; CETRIMIDE; CHITOSAN; CRL 1005; CYTOKINE; DNA VACCINE; DRUG CARRIER; DRUG VEHICLE; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; HEAT SHOCK PROTEIN 70; IMMUNOLOGICAL ADJUVANT; IMMUNOSTIMULATING AGENT; INTERLEUKIN 2; LIPOSOME; MICROPARTICLE; MICROSPHERE; NANOPARTICLE; PHOSPHORYL LIPID A; PLASMID DNA; POLOXAMER; POLY(BETA AMINO ESTER); POLYETHYLENEIMINE; POLYGLACTIN; POLYMER; POLYMETHACRYLIC ACID DERIVATIVE; POVIDONE; UNCLASSIFIED DRUG; UNINDEXED DRUG;

BACTERIAL INFECTION; CELLULAR IMMUNITY; DNA IMMUNIZATION; DRUG DELIVERY SYSTEM; DRUG FORMULATION; DRUG STRUCTURE; GENE EXPRESSION; GENE TARGETING; HUMAN; IMMUNOGENICITY; IMMUNOSTIMULATION; NONHUMAN; PRIORITY JOURNAL; REVIEW; VIRUS INFECTION;

ADJUVANTS, IMMUNOLOGIC; ANIMALS; DRUG CARRIERS; DRUG DELIVERY SYSTEMS; HUMANS; LIPOSOMES; NANOPARTICLES; PARTICLE SIZE; PLASMIDS; POLYMERS; VACCINES, DNA;

EID: 34247255391     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2007.01.120     Document Type: Review

References (138)

1. World Health Organization. Global Alliance for Vaccines and Immunization Factsheet. Rep. 169. World Health Organization; 2001.
2. Mascola J.R., Stiegler G., VanCott T.C., Katinger H., Carpenter C.B., Hanson C.E., et al. Protection of macaques against vaginal transmission of a pathogenic HIV-1/SIV chimeric virus by passive infusion of neutralizing antibodies. Nat Med 6 (2000) 207-210
3. Flynn J., Goldstein M., Triebold K., Koller B., and Bloom B. Major histocompatibility complex class I. Restricted T cells are required for resistance to Mycobacterium tuberculosis infection. PNAS 89 (1992) 12013-12017
4. Bojang K.A., Milligan P.J., Pinder M., Vigneron L., Alloueche A., Kester K.E., et al. Efficacy of RTS, S/AS02 malaria vaccine against Plasmodium falciparum infection in semi-immune adult men in The Gambia: a randomised trial. Lancet 358 (2001) 1927-1934
5. United Nations Population Division. HIV/AIDS: Population Impact and Policies, United Nations Population Division; 2001.
6. UNAIDS/WHO. AIDS epidemic update: December 2005. Geneva, Switzerland: UNAIDS/WHO; 2006.
7. Markel H. The search for effective HIV vaccines. N Engl J Med 353 (2005) 753-757
8. Sharpe S., Hanke T., Tinsley-Bown A., Dennis M., Dowall S., McMichael A., et al. Mucosal immunization with PLGA-microencapsulated DNA primes a SIV-specific CTL response revealed by boosting with cognate recombinant modified vaccinia virus Ankara. Virology 313 (2003) 13-21
9. Forde G.M. Rapid-response vaccines-does DNA offer a solution?. Nat Biotech 23 (2005) 1059-1062
10. Ulmer J.B., Donnelly J.J., Parker S.E., Rhodes G.H., Felgner P.L., Dwarki V.J., et al. Heterologous protection against influenza by injection of DNA encoding a viral protein. Science 259 (1993) 1745-1749
11. Wolff J.A., Malone R.W., Williams P., Chong W., Acsadi G., Jani A., et al. Direct gene transfer into mouse muscle in vivo. Science 247 (1990) 1465-1468
12. Krieg A.M. Direct immunologic activities of CpG DNA and implications for gene therapy. J Gene Med 1 (1999) 56-63
13. Donnelly J.J., Liu M.A., and Ulmer J.B. Antigen presentation and DNA vaccines. Am J Respir Crit Care Med 162 (2000) S190-S193
14. Dubensky Jr. T.W., Liu M.A., and Ulmer J.B. Delivery systems for gene-based vaccines. Mol Med 6 (2000) 723-732
15. Porgador A., Irvine K.R., Iwasaki A., Barber B.H., Restifo N.P., and Germain R.N. Predominant role for directly transfected dendritic cells in antigen presentation to CD8+ T cells after gene gun immunization. J Exp Med 188 (1998) 1075-1082
16. Corr M., Lee D.J., Carson D.A., and Tighe H. Gene vaccination with naked plasmid DNA: mechanism of CTL priming. J Exp Med 184 (1996) 1555-1560
17. Zur Megede J., Chen M.C., Doe B., Schaefer M., Greer C.E., Selby M., et al. Increased expression and immunogenicity of sequence-modified human immunodeficiency virus type 1 gag gene. J Virol 74 (2000) 2628-2635
18. Shah J.A., Darrah P.A., Ambrozak D.R., Turon T.N., Mendez S., Kirman J., et al. Dendritic cells are responsible for the capacity of CpG oligodeoxynucleotides to act as an adjuvant for protective vaccine immunity against Leishmania major in mice. J Exp Med 198 (2003) 281-291
19. Spies B., Hochrein H., Vabulas M., Huster K., Busch D.H., Schmitz F., et al. Vaccination with plasmid DNA activates dendritic cells via toll-like receptor 9 (TLR9) but functions in TLR9-deficient mice. J Immunol 171 (2003) 5908-5912
20. Okabe Y., Kawane K., Akira S., Taniguchi T., and Nagata S. Toll-like receptor-independent gene induction program activated by mammalian DNA escaped from apoptotic DNA degradation. J Exp Med 202 (2005) 1333-1339
21. Wagner H., and Bauer S. All is not Toll: new pathways in DNA recognition. J Exp Med 203 (2006) 265-268
22. Fynan E.F., Webster R.G., Fuller D.H., Haynes J.R., Santoro J.C., and Robinson H.L. DNA vaccines: protective immunizations by parenteral, mucosal, and gene-gun inoculations. Proc Natl Acad Sci USA 90 (1993) 11478-11482
23. McCluskie M.J., Brazolot Millan C.L., Gramzinski R.A., Robinson H.L., Santoro J.C., Fuller J.T., et al. Route and method of delivery of DNA vaccine influence immune responses in mice and non-human primates. Mol Med 5 (1999) 287-300
24. Wang B., Dang K., Agadjanyan M.G., Srikantan V., Li F., Ugen K.E., et al. Mucosal immunization with a DNA vaccine induces immune responses against HIV-1 at a mucosal site. Vaccine 15 (1997) 821-825
25. Chen S.C., Jones D.H., Fynan E.F., Farrar G.H., Clegg J.C., Greenberg H.B., et al. Protective immunity induced by oral immunization with a rotavirus DNA vaccine encapsulated in microparticles. J Virol 72 (1998) 5757-5761
26. Jones D.H., Partidos C.D., Steward M.W., and Farrar G.H. Oral delivery of poly(lactide-co-glycolide) encapsulated vaccines. Behring Inst Mitt (1997) 220-228
27. Tagawa S.T., Lee P., Snively J., Boswell W., Ounpraseuth S., Lee S., et al. Phase I study of intranodal delivery of a plasmid DNA vaccine for patients with stage IV melanoma. Cancer 98 (2003) 144-154
28. Tuting T., Storkus W.J., and Falo Jr. L.D. DNA immunization targeting the skin: molecular control of adaptive immunity. J Invest Dermatol 111 (1998) 183-188
29. Putkonen P., Quesada-Rolander M., Leandersson A.C., Schwartz S., Thorstensson R., Okuda K., et al. Immune responses but no protection against SHIV by gene-gun delivery of HIV-1 DNA followed by recombinant subunit protein boosts. Virology 250 (1998) 293-301
30. Polack F.P., Lee S.H., Permar S., Manyara E., Nousari H.G., Jeng Y., et al. Successful DNA immunization against measles: neutralizing antibody against either the hemagglutinin or fusion glycoprotein protects rhesus macaques without evidence of atypical measles. Nat Med 6 (2000) 776-781
31. Bins A.D., Jorritsma A., Wolkers M.C., Hung C.-F., Wu T.-C., Schumacher T.N.M., et al. A rapid and potent DNA vaccination strategy defined by in vivo monitoring of antigen expression. Nat Med 11 (2005) 899-904
32. Otten G.R., Doe B., Schaefer M., Chen M., Selby M.J., Goldbeck C., et al. Relative potency of cellular and humoral immune responses induced by DNA vaccination. Intervirology 43 (2000) 227-232
33. Liu M.A., McClements W., Ulmer J.B., Shiver J., and Donnelly J. Immunization of non-human primates with DNA vaccines. Vaccine 15 (1997) 909-912
34. Wang R., Doolan D.L., Le T.P., Hedstrom R.C., Coonan K.M., Charoenvit Y., et al. Induction of antigen-specific cytotoxic T lymphocytes in humans by a malaria DNA vaccine. Science 282 (1998) 476-480
35. Dupuis M., Denis-Mize K., Woo C., Goldbeck C., Selby M.J., Chen M., et al. Distribution of DNA vaccines determines their immunogenicity after intramuscular injection in mice. J Immunol 165 (2000) 2850-2858
36. Liu F., Song Y., and Liu D. Hydrodynamics-based transfection in animals by systemic administration of plasmid DNA. Gene Ther 6 (1999) 1258-1266
37. Bureau M.F., Naimi S., Torero Ibad R., Seguin J., Georger C., Arnould E., et al. Intramuscular plasmid DNA electrotransfer: biodistribution and degradation. Biochim Biophys Acta 1676 (2004) 138-148
38. McAdam A.J., Schweitzer A.N., and Sharpe A.H. The role of B7 co-stimulation in activation and differentiation of CD4+ and CD8+ T cells. Immunol Rev 165 (1998) 231-247
39. Asea A., Rehli M., Kabingu E., Boch J.A., Bare O., Auron P.E., et al. Novel signal transduction pathway utilized by extracellular HSP70: role of toll-like receptor (TLR) 2 and TLR4. J Biol Chem 277 (2002) 15028-15034
40. Planelles L., Thomas M.C., Alonso C., and Lopez M.C. DNA immunization with Trypanosoma cruzi HSP70 fused to the KMP11 protein elicits a cytotoxic and humoral immune response against the antigen and leads to protection. Infect Immun 69 (2001) 6558-6563
41. Morrison D.C., Silverstein R., Luchi M., and Shnyra A. Structure-function relationships of bacterial endotoxins. Contribution to microbial sepsis. Infect Dis Clin N Am 13 (1999) 313-340
42. Ray N.B., Ewalt L.C., and Lodmell D.L. Nanogram quantities of plasmid DNA encoding the rabies virus glycoprotein protect mice against lethal rabies virus infection. Vaccine 15 (1997) 892-895
43. Lodmell D.L., Ray N.B., Ulrich J.T., and Ewalt L.C. DNA vaccination of mice against rabies virus: effects of the route of vaccination and the adjuvant monophosphoryl lipid A (MPL). Vaccine 18 (2000) 1059-1066
44. Shiver J.W., Fu T.M., Chen L., Casimiro D.R., Davies M.E., Evans R.K., et al. Replication-incompetent adenoviral vaccine vector elicits effective anti-immunodeficiency-virus immunity. Nature 415 (2002) 331-335
45. Lindblad E.B. Aluminium compounds for use in vaccines. Immunol Cell Biol 82 (2004) 497-505
46. Ulmer J.B., DeWitt C.M., Chastain M., Friedman A., Donnelly J.J., McClements W.L., et al. Enhancement of DNA vaccine potency using conventional aluminum adjuvants. Vaccine 18 (1999) 18-28
47. Shiver JW. Development of an HIV-1 vaccine based on replication-defective adenovirus. Presented at keystone symposium: HIV vaccine development; 2004.
48. Barouch D.H., Letvin N.L., and Seder R.A. The role of cytokine DNAs as vaccine adjuvants for optimizing cellular immune responses. Immunol Rev 202 (2004) 266-274
49. Kim J.J., Trivedi N.N., Nottingham L.K., Morrison L., Tsai A., Hu Y., et al. Modulation of amplitude and direction of in vivo immune responses by co-administration of cytokine gene expression cassettes with DNA immunogens. Eur J Immunol 28 (1998) 1089-1103
50. Xin K.Q., Hamajima K., Sasaki S., Tsuji T., Watabe S., Okada E., et al. IL-15 expression plasmid enhances cell-mediated immunity induced by an HIV-1 DNA vaccine. Vaccine 17 (1999) 858-866
51. Seaman M.S., Peyerl F.W., Jackson S.S., Lifton M.A., Gorgone D.A., Schmitz J.E., et al. Subsets of memory cytotoxic T lymphocytes elicited by vaccination influence the efficiency of secondary expansion in vivo. J Virol 78 (2004) 206-215
52. Smith K.A. T-cell growth factor. Immunol Rev 51 (1980) 337-357
53. Barouch D.H., Santra S., Schmitz J.E., Kuroda M.J., Fu T.M., Wagner W., et al. Control of viremia and prevention of clinical AIDS in rhesus monkeys by cytokine-augmented DNA vaccination. Science 290 (2000) 486-492
54. Kim J.J., Nottingham L.K., Sin J.I., Tsai A., Morrison L., Oh J., et al. CD8 positive T cells influence antigen-specific immune responses through the expression of chemokines. J Clin Invest 102 (1998) 1112-1124
55. Sin J., Kim J.J., Pachuk C., Satishchandran C., and Weiner D.B. DNA vaccines encoding interleukin-8 and RANTES enhance antigen-specific Th1-type CD4(+) T-cell-mediated protective immunity against herpes simplex virus type 2 in vivo. J Virol 74 (2000) 11173-11180
56. Barouch D.H., McKay P.F., Sumida S.M., Santra S., Jackson S.S., Gorgone D.A., et al. Plasmid chemokines and colony-stimulating factors enhance the immunogenicity of DNA priming-viral vector boosting human immunodeficiency virus type 1 vaccines. J Virol 77 (2003) 8729-8735
57. Sumida S.M., McKay P.F., Truitt D.M., Kishko M.G., Arthur J.C., Seaman M.S., et al. Recruitment and expansion of dendritic cells in vivo potentiate the immunogenicity of plasmid DNA vaccines. J Clin Invest 114 (2004) 1334-1342
58. McKay P.F., Barouch D.H., Santra S., Sumida S.M., Jackson S.S., Gorgone D.A., et al. Recruitment of different subsets of antigen-presenting cells selectively modulates DNA vaccine-elicited CD4+ and CD8+ T lymphocyte responses. Eur J Immunol 34 (2004) 1011-1020
59. Pavlenko M., Roos A.K., Lundqvist A., Palmborg A., Miller A.M., Ozenci V., et al. A phase I trial of DNA vaccination with a plasmid expressing prostate-specific antigen in patients with hormone-refractory prostate cancer. Br J Cancer 91 (2004) 688-694
60. Brave A., Ljungberg K., Boberg A., Rollman E., Isaguliants M., Lundgren B., et al. Multigene/multisubtype HIV-1 vaccine induces potent cellular and humoral immune responses by needle-free intradermal delivery. Mol Ther 12 (2005) 1197-1205
61. Chang D.Z., Lomazow W., Joy Somberg C., Stan R., and Perales M.A. Granulocyte-macrophage colony stimulating factor: an adjuvant for cancer vaccines. Hematology 9 (2004) 207-215
62. Xiang Z., and Ertl H.C. Manipulation of the immune response to a plasmid-encoded viral antigen by coinoculation with plasmids expressing cytokines. Immunity 2 (1995) 129-135
63. Barouch D.H., Santra S., Tenner-Racz K., Racz P., Kuroda M.J., Schmitz J.E., et al. Potent CD4+ T cell responses elicited by a bicistronic HIV-1 DNA vaccine expressing gp120 and GM-CSF. J Immunol 168 (2002) 562-568
64. Sin J.I., Kim J.J., Ugen K.E., Ciccarelli R.B., Higgins T.J., and Weiner D.B. Enhancement of protective humoral (Th2) and cell-mediated (Th1) immune responses against herpes simplex virus-2 through co-delivery of granulocyte-macrophage colony-stimulating factor expression cassettes. Eur J Immunol 28 (1998) 3530-3540
65. Wang R., Richie T.L., Baraceros M.F., Rahardjo N., Gay T., Banania J.G., et al. Boosting of DNA vaccine-elicited gamma interferon responses in humans by exposure to malaria parasites. Infect Immun 73 (2005) 2863-2872
66. Heinzerling L., Basch V., Maloy K., Johansen P., Senti G., Wuthrich B., et al. Critical role for DNA vaccination frequency in induction of antigen-specific cytotoxic responses. Vaccine 24 (2006) 1389-1394
67. Moskophidis D., Lechner F., Pircher H., and Zinkernagel R.M. Virus persistence in acutely infected immunocompetent mice by exhaustion of antiviral cytotoxic effector T cells. Nature 362 (1993) 758-761
68. Wherry E.J., Teichgraber V., Becker T.C., Masopust D., Kaech S.M., Antia R., et al. Lineage relationship and protective immunity of memory CD8 T cell subsets. Nat Immunol 4 (2003) 225-234
69. Miller M., Rekas G., Dayball K., Wan Y.H., and Bramson J. The efficacy of electroporated plasmid vaccines correlates with long-term antigen production in vivo. Vaccine 22 (2004) 2517-2523
70. Wherry E.J., Puorro K.A., Porgador A., and Eisenlohr L.C. The induction of virus-specific CTL as a function of increasing epitope expression: responses rise steadily until excessively high levels of epitope are attained. J Immunol 163 (1999) 3735-3745
71. Greenland J.R., Liu H., Berry D., Anderson D.G., Kim W.K., Irvine D.J., et al. Beta-amino ester polymers facilitate in vivo DNA transfection and adjuvant plasmid DNA immunization. Mol Ther 12 (2005) 164-170
72. Manthorpe M., Cornefert-Jensen F., Hartikka J., Felgner J., Rundell A., Margalith M., et al. Gene therapy by intramuscular injection of plasmid DNA: studies on firefly luciferase gene expression in mice. Hum Gene Ther 4 (1993) 419-431
73. Norman J.A., Hobart P., Manthorpe M., Felgner P., and Wheeler C. Development of improved vectors for DNA-based immunization and other gene therapy applications. Vaccine 15 (1997) 801-803
74. Chapman B.S., Thayer R.M., Vincent K.A., and Haigwood N.L. Effect of intron A from human cytomegalovirus (Towne) immediate-early gene on heterologous expression in mammalian cells. Nucleic Acids Res 19 (1991) 3979-3986
75. Grosjean H., and Fiers W. Preferential codon usage in prokaryotic genes: the optimal codon-anticodon interaction energy and the selective codon usage in efficiently expressed genes. Gene 18 (1982) 199-209
76. Andre S., Seed B., Eberle J., Schraut W., Bultmann A., and Haas J. Increased immune response elicited by DNA vaccination with a synthetic gp120 sequence with optimized codon usage. J Virol 72 (1998) 1497-1503
77. Babiuk S., Baca-Estrada M.E., Foldvari M., Middleton D.M., Rabussay D., Widera G., et al. Increased gene expression and inflammatory cell infiltration caused by electroporation are both important for improving the efficacy of DNA vaccines. J Biotechnol 110 (2004) 1-10
78. Gao X., and Huang L. Cationic liposome-mediated gene transfer. Gene Ther 2 (1995) 710-722
79. Nakanishi M., and Noguchi A. Confocal and probe microscopy to study gene transfection mediated by cationic liposomes with a cationic cholesterol derivative. Adv Drug Deliv Rev 52 (2001) 197-207
80. Hyde S.C., Southern K.W., Gileadi U., Fitzjohn E.M., Mofford K.A., Waddell B.E., et al. Repeat administration of DNA/liposomes to the nasal epithelium of patients with cystic fibrosis. Gene Ther 7 (2000) 1156-1165
81. Nabel G.J., Nabel E.G., Yang Z.Y., Fox B.A., Plautz G.E., Gao X., et al. Direct gene transfer with DNA-liposome complexes in melanoma: expression, biologic activity, and lack of toxicity in humans. Proc Natl Acad Sci USA 90 (1993) 11307-11311
82. Perrie Y., Frederik P.M., and Gregoriadis G. Liposome-mediated DNA vaccination: the effect of vesicle composition. Vaccine 19 (2001) 3301-3310
83. Mannino R.J., Canki M., Feketeova E., Scolpino A.J., Wang Z., Zhang F., et al. Targeting immune response induction with cochleate and liposome-based vaccines. Adv Drug Deliv Rev 32 (1998) 273-287
84. Yamano T., Kaneda Y., Huang S., Hiramatsu S.H., and Hoon D.S. Enhancement of immunity by a DNA melanoma vaccine against TRP2 with CCL21 as an adjuvant. Mol Ther 13 (2006) 194-202
85. Somavarapu S., Bramwell V.W., and Alpar H.O. Oral plasmid DNA delivery systems for genetic immunization. J Drug Target 11 (2003) 547-553
86. Perrie Y., Obrenovic M., McCarthy D., and Gregoriadis G. Liposome (lipodine)-mediated DNA vaccination by the oral route. J Liposome Res 12 (2002) 185-197
87. Wang D., Christopher M.E., Nagata L.P., Zabielski M.A., Li H., Wong J.P., et al. Intranasal immunization with liposome-encapsulated plasmid DNA encoding influenza virus hemagglutinin elicits mucosal, cellular and humoral immune responses. J Clin Virol 31 Suppl 1 (2004) S99-S106
88. Dow S.W., Fradkin L.G., Liggitt D.H., Willson A.P., Heath T.D., and Potter T.A. Lipid-DNA complexes induce potent activation of innate immune responses and antitumor activity when administered intravenously. J Immunol 163 (1999) 1552-1561
89. Zhou W.Z., Kaneda Y., Huang S., Morishita R., and Hoon D. Protective immunization against melanoma by gp100 DNA-HVJ-liposome vaccine. Gene Ther 6 (1999) 1768-1773
90. Perrie Y., McNeil S., and Vangala A. Liposome-mediated DNA immunisation via the subcutaneous route. J Drug Target 11 (2003) 555-563
91. Lanuti M., Rudginsky S., Force S.D., Lambright E.S., Siders W.M., Chang M.Y., et al. Cationic lipid:bacterial DNA complexes elicit adaptive cellular immunity in murine intraperitoneal tumor models. Cancer Res 60 (2000) 2955-2963
92. Whitmore M., Li S., and Huang L. LPD lipopolyplex initiates a potent cytokine response and inhibits tumor growth. Gene Ther 6 (1999) 1867-1875
93. Cui Z., Han S.J., Vangasseri D.P., and Huang L. Immunostimulation mechanism of LPD nanoparticle as a vaccine carrier. Mol Pharm 2 (2005) 22-28
94. Perrie Y., and Gregoriadis G. Liposome-entrapped plasmid DNA: characterisation studies. Biochim Biophys Acta 1475 (2000) 125-132
95. Mastrobattista E., Kapel R.H., Eggenhuisen M.H., Roholl P.J., Crommelin D.J., Hennink W.E., et al. Lipid-coated polyplexes for targeted gene delivery to ovarian carcinoma cells. Cancer Gene Ther 8 (2001) 405-413
96. Ledley F.D. Pharmaceutical approach to somatic gene therapy. Pharm Res 13 (1996) 1595-1614
97. Lungwitz U., Breunig M., Blunk T., and Gopferich A. Polyethylenimine-based non-viral gene delivery systems. Eur J Pharm Biopharm 60 (2005) 247-266
98. Boussif O., Lezoualc'h F., Zanta M.A., Mergny M.D., Scherman D., Demeneix B., et al. A versatile vector for gene and oligonucleotide transfer into cells in culture and in vivo: polyethylenimine. Proc Natl Acad Sci USA 92 (1995) 7297-7301
99. Tsubokawa N., Asano I., and Sone Y. Cationic ring-opening polymerization of 2-substituted-2-oxazolines initiated by carbon black surface. Polym Bull 18 (1987) 377-384
100. Zhong Z., Feijen J., Lok M.C., Hennink W.E., Christensen L.V., Yockman J.W., et al. Low molecular weight linear polyethylenimine-b-poly(ethylene glycol)-b-polyethylenimine triblock copolymers: synthesis, characterization, and in vitro gene transfer properties. Biomacromolecules 6 (2005) 3440-3448
101. Goula D., Benoist C., Mantero S., Merlo G., Levi G., and Demeneix B.A. Polyethylenimine-based intravenous delivery of transgenes to mouse lung. Gene Ther 5 (1998) 1291-1295
102. Garzon M.R., Berraondo P., Crettaz J., Ochoa L., Vera M., Lasarte J.J., et al. Induction of gp120-specific protective immune responses by genetic vaccination with linear polyethylenimine-plasmid complex. Vaccine 23 (2005) 1384-1392
103. Anderson D.G., Peng W., Akinc A., Hossain N., Kohn A., Padera R., et al. A polymer library approach to suicide gene therapy for cancer. Proc Natl Acad Sci USA 101 (2004) 16028-16033
104. Funhoff A.M., Monge S., Teeuwen R., Koning G.A., Schuurmans-Nieuwenbroek N.M., Crommelin D.J., et al. PEG shielded polymeric double-layered micelles for gene delivery. J Control Release 102 (2005) 711-724
105. Funhoff A.M., van Nostrum C.F., Lok M.C., Kruijtzer J.A., Crommelin D.J., and Hennink W.E. Cationic polymethacrylates with covalently linked membrane destabilizing peptides as gene delivery vectors. J Control Release 101 (2005) 233-246
106. Bos G.W., Kanellos T., Crommelin D.J., Hennink W.E., and Howard C.R. Cationic polymers that enhance the performance of HbsAg DNA in vivo. Vaccine 23 (2004) 460-469
107. Pun S.H., and Davis M.E. Development of a nonviral gene delivery vehicle for systemic application. Bioconjugate Chem 13 (2002) 630-639
108. Pun S.H., Bellocq N.C., Liu A., Jensen G., Machemer T., Quijano E., et al. Cyclodextrin-modified polyethylenimine polymers for gene delivery. Bioconjugate Chem 15 (2004) 831-840
109. Heidel J.D., Hu S., Liu X.F., Triche T.J., and Davis M.E. Lack of interferon response in animals to naked siRNAs. Nat Biotechnol 22 (2004) 1579-1582
110. Lynn D.M., and Langer R. Degradable poly(β-amino esters): synthesis, characterization, and self-assembly with plasmid DNA. J Am Chem Soc 122 (2000) 10761-10768
111. Anderson D.G., Lynn D.M., and Langer R. Semi-automated synthesis and screening of a large library of degradable cationic polymers for gene delivery. Angew Chem Int Ed Engl 42 (2003) 3153-3158
112. Lynn D.M., Anderson D.G., Putnam D., and Langer R. Accelerated discovery of synthetic transfection vectors: parallel synthesis and screening of a degradable polymer library. J Am Chem Soc 123 (2001) 8155-8156
113. Evans R.K., Zhu D.-M., Casimiro D.R., Nawrocki D.K., Mach H., Troutman R.D., et al. Characterization and biological evaluation of a microparticle adjuvant formulation for plasmid DNA vaccines. J Pharm Sci 93 (2004) 1924-1939
114. Newman M.J., Actor J.K., Balusubramanian M., and Jagannath C. Use of nonionic block copolymers in vaccines and therapeutics. Crit Rev Ther Drug Carrier Syst 15 (1998) 89-142
115. Lemieux P., Guerin N., Paradis G., Proulx R., Chistyakova L., Kabanov A., et al. A combination of poloxamers increases gene expression of plasmid DNA in skeletal muscle. Gene Ther 7 (2000) 986-991
116. Lemieux P., Vinogradov S.V., Gebhart C.L., Guerin N., Paradis G., Nguyen H.K., et al. Block and graft copolymers and NanoGel copolymer networks for DNA delivery into cell. J Drug Target 8 (2000) 91-105
117. Kataoka K., Harada A., and Nagasaki Y. Block copolymer micelles for drug delivery: design, characterization and biological significance. Adv Drug Deliv Rev 47 (2001) 113-131
118. Katz J.M., Lu X., Todd C.W., and Newman M.J. A nonionic block co-polymer adjuvant (CRL1005) enhances the immunogenicity and protective efficacy of inactivated influenza vaccine in young and aged mice. Vaccine 18 (2000) 2177-2187
119. Casimiro D.R., Chen L., Fu T.M., Evans R.K., Caulfield M.J., Davies M.E., et al. Comparative immunogenicity in rhesus monkeys of DNA plasmid, recombinant vaccinia virus, and replication-defective adenovirus vectors expressing a human immunodeficiency virus type 1 gag gene. J Virol 77 (2003) 6305-6313
120. Mumper R.J., Duguid J.G., Anwer K., Barron M.K., Nitta H., and Rolland A.P. Polyvinyl derivatives as novel interactive polymers for controlled gene delivery to muscle. Pharm Res 13 (1996) 701-709
121. Zimecki M., Webb D.R., and Rogers T.J. The regulation of the immune response to polyvinylpyrollidone: antigen induced changes in prostaglandin and cyclic nucleotide levels. Arch Immunol Ther Exp (Warsz) 28 (1980) 179-197
122. Anwer K., Earle K.A., Shi M., Wang J., Mumper R.J., Proctor B., et al. Synergistic effect of formulated plasmid and needle-free injection for genetic vaccines. Pharm Res 16 (1999) 889-895
123. Denis-Mize K.S., Dupuis M., MacKichan M.L., Singh M., Doe B., O'Hagan D., et al. Plasmid DNA adsorbed onto cationic microparticles mediates target gene expression and antigen presentation by dendritic cells. Gene Ther 7 (2000) 2105-2112
124. Cui Z., and Mumper R.J. Microparticles and nanoparticles as delivery systems for DNA vaccines. Crit Rev Ther Drug Carrier Syst 20 (2003) 103-137
125. Hedley M.L., Curley J., and Urban R. Microspheres containing plasmid-encoded antigens elicit cytotoxic T-cell responses. Nat Med 4 (1998) 365-368
126. Klencke B., Matijevic M., Urban R.G., Lathey J.L., Hedley M.L., Berry M., et al. Encapsulated plasmid DNA treatment for human papillomavirus 16-associated anal dysplasia: a phase I study of ZYC101. Clin Cancer Res 8 (2002) 1028-1037
127. Jang J.H., and Shea L.D. Intramuscular delivery of DNA releasing microspheres: microsphere properties and transgene expression. J Control Release 112 (2006) 120-128
128. Barman S.P., Lunsford L., Chambers P., and Hedley M.L. Two methods for quantifying DNA extracted from poly(lactide-co-glycolide) microspheres. J Control Release 69 (2000) 337-344
129. Fu K., Pack D.W., Klibanov A.M., and Langer R. Visual evidence of acidic environment within degrading poly(lactic-co-glycolic acid) (PLGA) microspheres. Pharm Res 17 (2000) 100-106
130. Singh M., Briones M., Ott G., and O'Hagan D. Cationic microparticles: a potent delivery system for DNA vaccines. Proc Natl Acad Sci USA 97 (2000) 811-816
131. Denis-Mize K.S., Dupuis M., Singh M., Woo C., Ugozzoli M., O'Hagan D.T., et al. Mechanisms of increased immunogenicity for DNA-based vaccines adsorbed onto cationic microparticles. Cell Immunol 225 (2003) 12-20
132. O'Hagan D., Singh M., Ugozzoli M., Wild C., Barnett S., Chen M., et al. Induction of potent immune responses by cationic microparticles with adsorbed human immunodeficiency virus DNA vaccines. J Virol 75 (2001) 9037-9043
133. Little S.R., Lynn D.M., Ge Q., Anderson D.G., Puram S.V., Chen J., et al. Poly-beta amino ester-containing microparticles enhance the activity of nonviral genetic vaccines. Proc Natl Acad Sci USA 101 (2004) 9534-9539
134. Aggarwal N., HogenEsch H., Guo P., North A., Suckow M., and Mittal S.K. Biodegradable alginate microspheres as a delivery system for naked DNA. Can J Vet Res 63 (1999) 148-152
135. Mittal S.K., Aggarwal N., Sailaja G., van Olphen A., HogenEsch H., North A., et al. Immunization with DNA, adenovirus or both in biodegradable alginate microspheres: effect of route of inoculation on immune response. Vaccine 19 (2000) 253-263
136. Iqbal M., Lin W., Jabbal-Gill I., Davis S.S., Steward M.W., and Illum L. Nasal delivery of chitosan-DNA plasmid expressing epitopes of respiratory syncytial virus (RSV) induces protective CTL responses in BALB/c mice. Vaccine 21 (2003) 1478-1485
137. Roy K., Mao H.Q., Huang S.K., and Leong K.W. Oral gene delivery with chitosan-DNA nanoparticles generates immunologic protection in a murine model of peanut allergy. Nat Med 5 (1999) 387-391
138. Wang C., Ge Q., Ting D., Nguyen D., Shen H.R., Chen J., et al. Molecularly engineered poly(ortho ester) microspheres for enhanced delivery of DNA vaccines. Nat Mater 3 (2004) 190-196